Breye's $73M Raise: A Game-Changer for Eye Care?

Jan de Vries · 2026-10-02

Breye Therapeutics, a Danish biopharmaceutical company, just closed an oversubscribed $73 million Series A round. That's a big deal for a company developing oral treatments for retinal diseases. Let's break down why this matters. ### The Funding Round: Who's Betting Big? The round was co-led by Mission BioCapital and Novo Holdings, with existing investor Sound Bioventures and new investors like the Ljungström family office, Innovestor Life Science, EIFO, Catalyze Capital, Modi Ventures, and Pappas Capital. As part of the deal, Robert Blazej from Mission BioCapital and Lukas Ljungström will join Breye's board. Ulrik Mouritzen, CEO of Breye, said: "This $73 million Series A financing, which includes significant support from both new and existing investors, reflects the strong confidence in Breye's vision, strategy, and pipeline. It marks a major milestone for the Company and validates the enormous progress we have made to date. Importantly, it enables us to advance danegaptide, our pioneering, first-in-class oral treatment for diabetic retinopathy, to the next stage of clinical development – bringing a much-needed patient-friendly treatment option closer to those living with this debilitating eye disease." ### What Breye Is Working On Breye was founded in 2019 and emerged from stealth in November 2022 after a $4.3 million seed round. The company is developing oral therapies for eye diseases like intermediate age-related macular degeneration and glaucoma. Diabetic retinopathy is a leading cause of vision loss among working-age adults, affecting about 130 million people worldwide. The market for diabetic retinopathy therapeutics is nearing $10 billion and could double in the next decade. Current treatments for late-stage disease involve injections directly into the eye, which are invasive and often poorly tolerated. For early or moderate stages, options are limited. Breye's lead candidate, danegaptide, is an oral small molecule that stabilizes retinal vasculature, potentially protecting against capillary breakdown and leakage caused by high glucose levels. ### Promising Early Results The funding follows a successful Phase 1b trial in patients with non-proliferative diabetic retinopathy (NPDR). Danegaptide was well tolerated across all dose levels and showed early signs of clinical activity, including retinal imaging data consistent with reduced vascular leakage. Breye also published a paper in Science Translational Medicine analyzing the evidence for danegaptide. Robert Blazej of Mission BioCapital commented: "Breye is emerging as a leader in the development of innovative retinal disease therapies, as demonstrated by the promising results from its recent Phase Ib study of danegaptide, and we are excited to support the Company at this pivotal stage of growth. With its highly differentiated approach, clear development strategy and experienced team, we believe Breye is uniquely positioned to address a significant unmet need." ### Why This Matters for Patients and Investors For patients, an oral treatment could mean a less invasive, more convenient option. For investors, Breye's progress signals a potential breakthrough in a growing market. With this funding, Breye can advance danegaptide to the next stage of clinical development, bringing hope to millions affected by retinal diseases. This round not only validates Breye's approach but also highlights the increasing interest in innovative biotech solutions. As the company moves forward, all eyes will be on its next milestones.